Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Oleg V. Tcheremissine

Oleg V. Tcheremissine

Carolinas HealthCare System, USA

Title: Developing an Alzheimer’s Clinical Trial Network with the Carolinas HealthCare System, a large fully integrated health care system

Biography

Biography: Oleg V. Tcheremissine

Abstract

Alzheimer’s Disease (AD) is a progressive neurogenerative disorder with a wide range of symptoms affecting memory, concentration, volition, and almost all aspects of human behavior. The prevalence of patients with AD is increasing due to an aging population. There is real possibility that without medical breakthroughs, the current 5.3 million Americans diagnosed will triple to 13.8 million by 2050. Delivery of compressive care is facing a crisis stemming from a combination of factors -- a growing demand for such care, insufficient number of those specialized in this therapeutic area, rising costs of care, the complexity of the diseases and lack of effective treatment. Despite massive research efforts in recent decades, new treatments for AD remain elusive. Since 1998, there have been more than 100 attempts to develop new pharmacological agents, and all have failed. Patient population included in these clinical trials typically suffered from mild-moderate AD. Most of them were initially diagnosed and treated by their primary care providers. Early identification of a cohort of those who will benefit from clinical trial participation by is a strategic priority. CHS has made an investment in developing a comprehensive dementia care though a collaboration of different service lines including Neurosciences, Behavioral Health, Primary Care and Geriatrics. This bidirectional reciprocity allows to align the process of drug development with information derived at the “point of care”, and provides an opportunity to further breech the “efficacy-effectiveness” gap, commonly defined as the differences between two populations of patients, those enrolled in clinical trials and those who will be treated in real clinical settings.